West Pharmaceutical Services, Inc. logo

West Pharmaceutical Services, Inc. (WST)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
384. 02
+1
+0.2611%
$
26.96B Market Cap
49.01 P/E Ratio
0.88% Div Yield
511,177 Volume
7.62 Eps
$ 383.02
Previous Close
Add Transaction
Day Range
380.23 386.64
Year Range
223.83 386.26
Want to track WST and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates

West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates

West Pharmaceutical Services (WST) came out with quarterly earnings of $1.82 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.83 per share a year ago.

Zacks | 1 year ago
Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?

Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?

West Pharmaceutical Services WST is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 22.52%.

Zacks | 1 year ago
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.

Zacks | 1 year ago
LH vs. WST: Which Stock Is the Better Value Option?

LH vs. WST: Which Stock Is the Better Value Option?

Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks | 1 year ago
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.

Zacks | 1 year ago
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now

WST continues to gain momentum due to its strength in the Pharma market unit. However, decline across its Generics and Biologics business units is concerning.

Zacks | 1 year ago
West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript

West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript

West Pharmaceutical Services, Inc. (NYSE:WST ) Q3 2024 Results Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants John Sweeney - Vice President, Investor Relations Eric Green - Chairman, President and Chief Executive Officer Bernard Birkett - Senior Vice President, Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Lawrence Solow - CJS Securities Michael Ryskin - BofA Global Research David Windley - Jefferies Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank Thomas DeBourcy - Nephron Research Operator Good day and thank you for standing by. Welcome to the Q3 2024 West Pharmaceutical Services Earnings Conference Call.

Seekingalpha | 1 year ago
West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend

West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend

On Thursday, West Pharmaceutical Services, Inc. WST reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50.

Benzinga | 1 year ago
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance

West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance

WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.

Zacks | 1 year ago
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates

West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates

West Pharmaceutical Services (WST) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $2.16 per share a year ago.

Zacks | 1 year ago
West Pharmaceutical raises annual profit forecast on demand for medical supplies

West Pharmaceutical raises annual profit forecast on demand for medical supplies

West Pharmaceutical Services raised its annual profit forecast on Thursday, after beating Wall Street estimates for quarterly revenue and profit, banking on rising demand for cartridges and syringes used to manufacture injectable therapies.

Reuters | 1 year ago
What's in Store for West Pharmaceutical in Q3 Earnings?

What's in Store for West Pharmaceutical in Q3 Earnings?

WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.

Zacks | 1 year ago
Loading...
Load More